Young-Sun Sohn

Abxign, Inc. was established in January 2008 and is located in Samsung Cancer Research building in Seoul National University. Abxign focused on the discovery and development of antibody therapeutics where by first or best-in-class therapies are introduced in large and growing markets with quality partners. Abxign has accumulated therapeutic antibody development technology and experience for many years and maintains relationships with domestic and foreign pharmaceutical companies specialized for each part of the development of antibody therapy. Based on these Abxign's network and technology, it will release the excellent antibodies in the world pharmaceutical market and extend the human life and contribute to improving the quality of life.